Tumor Suppressor Gene Therapy With CD122/CD132 Agonists for Resistant Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing tumor suppressor gene therapies face challenges such as non-specific expression, low-efficiency delivery, and genetic changes leading to aberrant silencing, limiting their effectiveness in cancer treatment.

Innovation Solution

A combination therapy involving nucleic acids encoding p53 and MDA-7, along with CD122/CD132 agonists, is administered to restore or amplify tumor suppressor function, using viral and non-viral delivery methods, and optionally combined with immune checkpoint inhibitors and oncolytic viruses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If single gene therapy is used to restore tumor suppressor function, then therapeutic specificity is improved, but treatment effectiveness deteriorates due to genetic changes and epigenetic dysregulations leading to aberrant silencing

Engineering Contradiction:

Improvetherapeutic specificityVSAvoidtreatment effectiveness

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent combines multiple tumor suppressor genes (p53, MDA-7, and other候选 genes) into a single gene therapy composition. This merging approach addresses the limitation of single gene therapy by simultaneously restoring multiple tumor suppressor functions, thereby overcoming the aberrant silencing issue and enhancing overall treatment effectiveness while maintaining therapeutic specificity.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The gene therapy composition is designed to be multi-functional by incorporating multiple tumor suppressor genes that can target different pathways and mechanisms. This universal approach allows the therapy to effectively combat various types of cancer and adapt to different genetic alterations, improving treatment effectiveness without compromising specificity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Ease of manufacture

If conventional delivery methods are used for gene therapy, then delivery simplicity is maintained, but delivery efficiency deteriorates

Engineering Contradiction:

Improvedelivery simplicityVSAvoiddelivery efficiency

Core Design Contradiction:

Ease of manufactureVSProductivity

Solution Approach 1:

The patent employs viral vectors (such as adenoviruses, retroviruses, and lentiviruses) as intermediary carriers to deliver the multi-gene therapy composition to target cells. These viral vectors significantly enhance delivery efficiency by utilizing their natural tropism and cellular entry mechanisms, while the overall system remains relatively simple in terms of manufacturing and administration.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Device complexity

If tumor suppressor gene therapy is administered alone, then treatment simplicity is maintained, but anti-tumor activity deteriorates

Engineering Contradiction:

Improvetreatment simplicityVSAvoidanti-tumor activity

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The therapy composition functions as a composite biological system where multiple genes work synergistically to enhance anti-tumor activity. This composite approach allows the treatment to target multiple pathways simultaneously, improving reliability without significantly increasing treatment complexity.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances anti-tumor activity by inducing apoptosis in cancer cells, overcoming resistance and achieving significant tumor regression, including systemic and abscopal effects on distant tumors.

Implementation Method 1

the CD122/CD132 agonist preferentially binds to the CD122/CD132 receptor complex

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 2

restoration of wild-type (wt) p53 function can induce apoptosis in cancer cells

Methodology Applied

Scientific EffectGene expression restoration:

Implementation Method 3

force expression of apoptosis-inducing genes offer promise for restoring this mode of cell death in tumor cells

Methodology Applied

Scientific EffectApoptosis induction:

Data Source

PatentUS20260049111A1Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer

Publication Date: 2026.02.19 MULTIVIR INC

AI summary

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD122/CD132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and/or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122/CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.